BIONEER Corp.

DUBLIN--( BUSINESS WIRE )--The "RNA Analysis / Transcriptomics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for RNA Analysis / Transcriptomics is estimated at US$7.9 Billion in 2023 and is projected to reach US$19.0 Billion by 2030, growing at a CAGR of 13.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the RNA analysis/transcriptomics market is driven by several factors, including the increasing demand for personalized medicine, advancements in sequencing technologies, and the rising prevalence of chronic diseases and cancer. The shift towards personalized medicine, which aims to tailor treatments based on an individual's genetic profile, has spurred the need for comprehensive transcriptomic analysis to identify disease-specific biomarkers and therapeutic targets. Continuous improvements in sequencing technologies, resulting in higher accuracy, throughput, and cost-effectiveness, have made transcriptomic studies more accessible and feasible for a broader range of applications. Additionally, the rising incidence of chronic diseases and cancer has increased the focus on understanding the molecular underpinnings of these conditions, driving the adoption of transcriptomics in research and clinical settings. Government initiatives and funding for genomics research, along with collaborations between academic institutions and pharmaceutical companies, are also contributing to the market`s expansion. As a result, the RNA analysis/transcriptomics field is poised for significant growth, with ongoing innovations and applications promising to enhance our understanding of biology and improve healthcare outcomes. Key Insights: Market Growth: Understand the significant growth trajectory of the RNA Analysis / Transcriptomics Reagents / Consumables segment, which is expected to reach US$9.7 Billion by 2030 with a CAGR of a 14.4%. The RNA Analysis / Transcriptomics Instruments segment is also set to grow at 11.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $2.9 Billion in 2023, and China, forecasted to grow at an impressive 14.3% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as Agilent Technologies, Inc., Beckman Coulter, Inc., bioMerieux SA, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 504 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $7.9 Billion Forecasted Market Value (USD) by 2030 $19 Billion Compound Annual Growth Rate 13.3% Regions Covered Global MARKET OVERVIEW Global Economic Update RNA-Oriented Projects Set to Increase Competition RNA Analysis / Transcriptomics - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) What is RNA-Seq Technology? A Prelude to Transcriptomics Technologies Global Market Prospects & Outlook PCR Emerges as the Leading Technology Drug Discovery Segment Poised to Lead the Global Market North America Emerges as the Major Regional Market World Brands Recent Market Activity MARKET TRENDS & DRIVERS Trend Towards Personalized Medicine Fuels Market Growth Global Personalized Medicine Market Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population Transcriptomics Assume Critical Importance amid Growing Prevalence of Chronic Diseases Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others Transcriptomics Applications in Disease and Diagnostic Profiling Increasing PCR Applications in Biotechnology Sector Progressive Growth of Omics Technologies: Opportunity for RNA Analysis/Transcriptomics Market The Growing Role of Transcriptomics in Oncology RNA Sequencing Critical for Cancer and Rare Diseases Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiovascular Research Bulk RNA Sequencing Single-Cell Sequencing Spatial Transcriptomics Single-Cell RNA-seq Technologies Witness Steady Growth The Evolution of scRNA-seq Growth of Long-Read Transcriptome Sequencing scRNA-seq for Autoimmune Inflammatory Rheumatic Diseases SPLiTseq Beneficial for Understanding Cause of Disease Gene Expression Microarray Technology Gains Ground Microfluidics-based Droplet Technologies Demonstrate Growth inDrops Approach Exhibits Growth Spatial Transcriptomics Market Witnesses Significant Growth Spatial Transcriptomic Data Analysis Next Generation Sequencing Offers Increased Accuracy for Transcriptomics Activity Single-cell NGS Witnesses Rapid Growth RNA Sequencing Benefits Fuel Market Prospects Blood Transcriptome Sequencing for Identifying Rare-Disease Genes Rising Focus on Toxicogenomics: Potential for RNA Analysis/Transcriptomics Markets Growing R&D Spending in Pharma and Biotechnology Sectors Presents Opportunities Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025 Technological Advancements & Innovations Fuel Market Growth Sci-Plex - A New Technique to Profile Gene Expression within Single Cells Introduction of Oxford Nanopore's Innovative Portable Sequencer for Sequencing Long Reads and RNA Molecules Improves Transcriptomic Analysis RNA-Combine, a Toolkit for More Comprehensively Analyzing Transcriptome Data Aging Demographics Present Opportunities for Transcriptomics Technologies Challenges Facing RNA/Transcriptomics Market FOCUS ON SELECT PLAYERS (Total 115 Featured) Agilent Technologies, Inc. Beckman Coulter, Inc. bioMerieux SA Analytik Jena AG Ambry Genetics Advanced Cell Diagnostics, Inc. Bioneer Corporation BioChain Institute, Inc. Akoya Biosciences, Inc. Acobiom ADS Biotec, Inc. BGI Genomics Co Ltd. 10X Genomics Biois Co Ltd Bertin Technologies, Sas For more information about this report visit https://www.researchandmarkets.com/r/bcmemu About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base. The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities' growth. Again, assistance in using the information is normally provided without additional charges. After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 120 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Key Market Trends Personalized medicine Pharmacogenomics Liquid biopsy Minimal residual disease testing Emergence of new economies with large markets Physician diagnostics being displaced by new intelligent diagnostic tests Key Topics Covered: 1 Market Guides 1.1 Cancer MDx - Strategic Situation Analysis 1.2 Guide for Executives, Marketing, and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 What are Molecular Diagnostics? 2.2 The Diagnostics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 Market Overview 3.1 Market Segments 3.1.1 Traditional Market Segmentation 3.1.2 Laboratory Focus and Segmentation 3.2 Industry Structure 3.2.1 Hospital Testing Share 3.2.2 Economies of Scale 3.2.3 Physician Office Labs 3.2.4 Physicians and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 New Diagnostics Create New Markets 4.1.2 New Roles for Diagnostics 4.1.3 The Aging Effect 4.1.4 Expanding the Pharmaceutical Toolbox 4.1.5 Regulatory Retreat 4.2 Factors Limiting Growth 4.2.1 Falling Prices 4.2.2 Lower Costs 4.2.3 Wellness has a Downside 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point Of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 4.3.11 Multiplexing and Foundation One 4.3.12 Pharmacogenomics Technology 4.3.13 Gene Editing and Gene Therapy 5 Molecular Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Grail Cancer Test Faces New Clinical Questions 5.3 Freenome Acquires Cancer Dx Firm Oncimmune 5.4 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology 5.5 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients 5.6 Digital Pathology Meets Cancer Sequencing 5.7 Exact Sciences Preps Expanded Oncology Portfolio 5.8 Qiagen Details Oncology Plans for Digital PCR Platform 5.9 Sema4 Exiting Reproductive Health Screening 5.10 Thermo Fisher Introduces Cancer Profiling Assay 5.11 Genomic Test IDs Cysts Likely to Progress to Cancer 5.12 Naveris to Commercialize Virus-Related Cancer Tests 5.13 Larger Liquid Biopsy Panels Loom 5.14 Halo Diagnostics to Offer Genomic Profiling Tests 5.15 BillionToOne Raises $125M 5.16 Local Cancer Genomic Profiling Options Grow 5.17 German MDx Firm Mainz Biomed Raises $10M in IPO 5.18 Guardant Health Q3 Revenues Up 27 Percent 5.19 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection 5.20 Nucleix to Invest in Early-Stage Lung Cancer Dx 5.21 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics 5.22 Grail Gets Approval for Galleri Multicancer Test 5.23 Finnish Firms to Form Point-of-Care Testing Firm 5.24 Datar Cancer Genetics Expands to Dx and Screening 5.25 HTG Molecular Diagnostics: HTG Transcriptome Panel 5.26 PacBio's Omniome Acquisition Shortens Path to Clinical 5.27 Invitae to Acquire Genosity for $200M 5.28 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 5.29 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience 5.30 Natera Revenues Grow 35 Percent 5.31 AnchorDx Closes $40M Financing Round 5.32 Exact Sciences Strategy for End-to-End Cancer Testing 5.33 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch 6 Profiles of Key MDx Companies 6.1 10x Genomics, Inc. 6.2 Abbott Laboratories 6.3 AccuraGen Inc. 6.4 Adaptive Biotechnologies 6.5 Aethlon Medical 6.6 Agilent/Dako 6.7 Anchor Dx 6.8 ANGLE plc 6.9 ARUP Laboratories 6.10 AVIVA Systems Biology 6.11 Baylor Miraca Genetics Laboratories 6.12 Beckman Coulter Diagnostics 6.13 Becton, Dickinson and Company 6.14 BGI Genomics Co. Ltd 6.15 BillionToOne 6.16 Bioarray Genetics 6.17 Biocartis 6.18 Biocept, Inc. 6.19 Biodesix Inc. 6.20 BioFluidica 6.21 BioGenex 6.22 BioIVT 6.23 Biolidics Ltd 6.24 bioMerieux Diagnostics 6.25 Bioneer Corporation 6.26 Bio-Rad Laboratories, Inc 6.27 Bio-Reference Laboratories 6.28 Bio-Techne 6.29 Bioview 6.30 Bolidics 6.31 Boreal Genomics 6.32 Bristol-Myers Squibb 6.33 Burning Rock 6.34 Cardiff Oncology 6.35 Caris Molecular Diagnostics 6.36 Castle Biosciences, Inc. 6.37 Celemics 6.38 CellCarta 6.39 CellMax Life 6.40 Cepheid (Danaher) 6.41 Charles River Laboratories 6.42 Circulogene 6.43 Cizzle Biotech 6.44 Clinical Genomics 6.45 Cytolumina Technologies Corp. 6.46 Datar Cancer Genetics Limited 6.47 Diagnologix LLC 6.48 Diasorin S.p.A. 6.49 Dxcover 6.50 Enzo Biochem 6.51 Epic Sciences 6.52 Epigenomics AG 6.53 Eurofins Scientific 6.54 Exact Sciences 6.55 Fabric Genomics 6.56 Fluxion Biosciences 6.57 Freenome 6.58 FUJIFILM Wako Diagnostics 6.59 Fulgent Genetics 6.60 Fyr Diagnostics 6.61 GeneFirst Ltd. 6.62 Genetron Holdings 6.63 GenomOncology 6.64 GILUPI Nanomedizin 6.65 Guardant Health 6.66 HansaBiomed 6.67 HeiScreen 6.68 Helomics 6.69 HTG Molecular Diagnostics 6.70 iCellate 6.71 ICON PLC 6.72 Illumina 6.73 Incell Dx 6.74 Inivata 6.75 INOVIQ 6.76 Integrated Diagnostics 6.77 Invitae Corporation 6.78 Invivogen 6.79 Invivoscribe 6.80 Janssen Diagnostics 6.81 Lunglife AI Inc 6.82 MDNA Life SCIENCES, Inc. 6.83 MDx Health 6.84 Menarini Silicon Biosystems 6.85 Mesa Laboratories, Inc. 6.86 Millipore Sigma 6.87 Miltenyi Biotec 6.88 miR Scientific 6.89 Myriad Genetics/Myriad RBM 6.90 NantHealth, Inc. 6.91 Natera 6.92 NeoGenomics 6.93 NGeneBio 6.94 Novogene Bioinformatics Technology Co., Ltd. 6.95 Oncocyte 6.96 OncoDNA 6.97 Ortho Clinical Diagnostics 6.98 Oxford Nanopore Technologies 6.99 PamGene 6.100 Panagene 6.101 Perkin Elmer 6.102 Personal Genome Diagnostics 6.103 Personalis 6.104 Precipio 6.105 Precision Medicine Group 6.106 PrecisionMed 6.107 Predicine 6.108 Promega 6.109 Qiagen 6.110 Rarecells SAS 6.111 RareCyte 6.112 Roche Molecular Diagnostics 6.113 Screencell 6.114 Sema4 Holdings 6.115 Sense Biodetection 6.116 Siemens Healthineers 6.117 simfo GmbH 6.118 Singlera Genomics Inc. 6.119 Singulomics 6.120 SkylineDx 6.121 Standard BioTools 6.122 Sysmex Inostics 6.123 Tempus Labs, Inc. 6.124 Thermo Fisher Scientific Inc. 6.125 Todos Medical 6.126 Variantyx 6.127 Veracyte 6.128 Volition 6.129 Vortex Biosciences 6.130 Vyant Bio 6.131 Zhejiang Orient Gene Biotech For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

DUBLIN--( BUSINESS WIRE )--The "Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides" report has been added to ResearchAndMarkets.com's offering. Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. Find out the latest outlook for this important market. Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. Science is racing forward. And the cost of molecular diagnostics continues to fall. "Companion Diagnostic Markets, the Future of Diagnostics" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the New Nucleic Acid Test Pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Specific growth and market size estimates for your area of interest is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report. Key Topics Covered: 1 Market Guides 1.1 Strategic Situation Analysis 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 What are Companion Diagnostics? 2.2 The Personalized Medicine Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Personalized Medicine and Companion Diagnostics 3.2.1 Basics 3.2.2 Method 3.2.3 Disease risk assessment 3.2.4 Applications 3.2.5 Diagnosis and intervention 3.2.5.1 Companion Diagnostics 3.2.6 Drug development and usage 3.2.7 Respiratory proteomics 3.2.8 Cancer genomics 3.2.9 Population screening 3.2.10 Challenges 3.2.11 Regulatory oversight 3.2.12 Intellectual property rights 3.2.13 Reimbursement policies 3.2.14 Patient privacy and confidentiality 3.3 Chromosomes, Genes and Epigenetics 3.3.1 Chromosomes 3.3.2 Genes 3.3.3 Epigenetics 3.4 Cancer Genes 3.4.1 Germline vs Somatic 3.4.2 Changing Clinical Role 3.5 Structure of Industry Plays a Part 3.5.1 New Pharmaceutical Funding Market 3.5.2 Economies of Scale 3.5.2.1 Hospital vs. Central Lab 3.5.3 Physician Office Labs 3.5.4 Physicians and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Level of Care 4.1.2 Immuno-oncology 4.1.3 Liability 4.1.4 The Aging World 4.2 Factors Limiting Growth 4.2.1 State of knowledge 4.2.2 Genetic Blizzard 4.2.3 Protocol Resistance 4.2.4 Regulation and coverage 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point Of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Companion Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 JaxBio to Create Array-Based Cancer Tests 5.3 Agilent, Qiagen Win FDA Approvals Companion Diagnostics 5.4 Navignostics Using Single-Cell Spatial Proteomics 5.5 HMNC Brain Health to Develop Companion Diagnostics 5.6 Propath UK, Nucleai Partner on Spatial Proteomics 5.7 Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics 5.8 Almac, AstraZeneca Strike CDx Development Pact 5.9 Avalon GloboCare, Lu Daopei Hematology Institute to Develop Cell Therapy CDx 5.10 Burning Rock Secures Lung Cancer NGS Test Approval in China 5.11 TenSixteen Bio Developing Drugs, Companion NGS Tests 5.12 Guardant Health Plans New Comprehensive Assay 5.13 Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs 5.14 Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test 5.15 Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx 5.16 Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug 5.17 Natera Aims to Lead Market in Solid Tumor Adjuvant CDx 5.18 Oncocyte Details Expansions Plans 5.19 Agilent Acquires Resolution Biosciences 5.20 Qiagen, Inovio Expand CDx Partnership 5.21 AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance 5.22 NeoGenomics to Grow Through CDx Agreements, Acquisitions 5.23 Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction 5.24 Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform 5.25 FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies 5.26 Promega to Develop MSI Assay as CDx 5.27 Guardant Health to Develop CDx for Janssen 5.28 Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx 5.29 FDA Approval for FoundationOneCDx 5.30 FDA finalizes CDx Guidance 5.31 QIAGEN Launches CDx Therascreen BRAF Test 6 Profiles of Key Players (Partial List) 10x Genomics, Inc Abbott Laboratories AccuraGen Inc Adaptive Biotechnologies Aethlon Medical Agilent/Dako Biocept, Inc Biodesix Inc BioFluidica BioGenex BioIVT Biolidics Ltd bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc CellMax Life Cepheid (Danaher) Charles River Laboratories Circulogene Dxcover Element Biosciences Enzo Biochem Epic Sciences Epigenomics AG Eurofins Scientific GILUPI Nanomedizin Guardant Health HansaBiomed HeiScreen Helomics HTG Molecular Diagnostics Invivoscribe Janssen Diagnostics Lunglife AI Inc MDNA Life SCIENCES, Inc MDx Health Menarini Silicon Biosystems Mesa Laboratories, Inc Natera NeoGenomics NGeneBio Novogene Bioinformatics Technology Co., Ltd Oncocyte OncoDNA Ortho Clinical Diagnostics Oxford Nanopore Technologies PamGene Panagene Perkin Elmer Qiagen Rarecells SAS RareCyte Roche Molecular Diagnostics Screencell Sema4 Holdings Sense Biodetection Siemens Healthineers simfo GmbH Stilla Technologies Sysmex Inostics Tempus Labs, Inc Thermo Fisher Scientific Inc Todos Medical Ultima Genomics Veracyte Volition Vortex Biosciences Vyant Bio For more information about this report visit https://www.researchandmarkets.com/r/61suqi About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.